Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage

References

• Hirashima Y, Kurimoto M, Takaba M, et al. The use of computed tomography in the prediction of delayed cerebral infarction following acute aneurysm surgery for subarachnoid haemorrhage. Acta Neurochir ( Wien) 1995; 132: 9–13
   PubMed Web of Science ®Google Scholar
• Ratsep T, Asser T. Cerebral hemodynamic impairment after aneurysmal subarachnoid hemorrhage as evaluated using tran-scranial Doppler ultrasonography: Relationship to delayed cere-bral ischemia and clinical outcome. J Neurosurg 2001; 95: 393–401
   PubMed Web of Science ®Google Scholar
• Rabinstein AA, Friedman JA, Weigand SD, et al. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2004; 35: 1862–1866
   PubMed Web of Science ®Google Scholar
• Mocco J, Zacharia BE, Komotar RJ, et al. A review of current andfuture medical therapies for cerebral vasospasm following aneur-ysmal subarachnoid hemorrhage. Neurosurg Focus 2006; 21: E9
   PubMedGoogle Scholar
• Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. Neurosurgery 2003; 53: 123–133
   PubMed Web of Science ®Google Scholar
• Wellman GC. Ion channels and calcium signaling in cerebral arteries following subarachnoid hemorrhage. Neurol Res 2006; 28: 690–702
   PubMed Web of Science ®Google Scholar
• Ostrowski RP, Colohan AR, Zhang JH. Molecular mechanisms ofearly brain injury after subarachnoid hemorrhage. Neurol Res 2006; 28: 399–414
   PubMed Web of Science ®Google Scholar
• Iseda K, Ono S, Onoda K, et al. Antivasospastic and antiin-flammatory effects of caspase inhibitor in experimental subar-achnoid hemorrhage. J Neurosurg 2007; 107: 128–135
   PubMed Web of Science ®Google Scholar
• Pluta RM. Dysfunction of nitric oxide synthases as a cause andtherapeutic target in delayed cerebral vasospasm after SAH. Neurol Res 2006; 28: 730–737
   PubMed Web of Science ®Google Scholar
• Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35: 1144–1149
   PubMed Web of Science ®Google Scholar
• Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type3 phosphodiesterase, produces endothelium-independent vasodila-tion in pressurized rabbit cerebral penetrating arterioles. J Vase Res 2006; 43: 86–94
   PubMed Web of Science ®Google Scholar
• Weintraub WS. The vascular effects of cilostazol. Can J Cardiol 2006; 22 (Suppl. B): 556B-560B
   Google Scholar
• Gao L, Wang F, Wang B, et al. Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther 2006; 318: 53–58
   PubMed Web of Science ®Google Scholar
• Kim MJ, Lee JH, Park SY, et al. Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via CAMP-dependent protein kinase activation. Pharmacol Res 2006; 54: 261–267
   PubMed Web of Science ®Google Scholar
• Ye YL, Shi WZ, Zhang WP, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries. Eur J Pharmacol 2007; 557: 23–31
   PubMed Web of Science ®Google Scholar
• Gules I, Satoh M, Clower BR, et al. Comparison of three rat models of cerebral vasospasm. Am J Physiol Heart Circ Physiol 2002; 283: H2551—H2559
   PubMed Web of Science ®Google Scholar
• Iyonaga K, Takeya M, Yamamoto T, et al. A novel monoclonal antibody, RM-4, specifically recognizes rat macrophages and dendritic cells in formalin-fixed, paraffin-embedded tissues. Histochem J 1997; 29: 105–116
   PubMedGoogle Scholar
• Tanaka K, Gotoh F, Fukuuchi Y, et al. Effects of a selective inhibitor of cyclic amp phosphodiesterase on the pial microcircula-tion in feline cerebral ischemia. Stroke 1989; 20: 668–673
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Kanmura Y, Itoh T. Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2±1; and force in middle cerebral artery of the rabbit. Br J Pharmacol 1998; 123: 869–878
   PubMed Web of Science ®Google Scholar
• Aizawa T, Wei H, Miano JM, et al. Role of phosphodiesterase 3 in NO/CGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 2003; 93: 406–413
   PubMed Web of Science ®Google Scholar
• Watanabe T, Zhang N, Liu M, et al. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 2006; 37: 1539–1545
   PubMed Web of Science ®Google Scholar
• Lee JH, Oh GT, Park SY, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 2005; 313: 502–509
   PubMed Web of Science ®Google Scholar
• Bavbek M, Polin R, Kwan AL, et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke 1998; 29: 1930–1935
   PubMed Web of Science ®Google Scholar
• Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol 2002; 88: 227–249
   PubMedGoogle Scholar
• Mack WJ, Mocco J, Hoh DJ, et al. Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subar-achnoid hemorrhage. J Neurosurg 2002; 96: 71-75
   Google Scholar
• Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebralvasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 2003; 99: 376–382
   PubMed Web of Science ®Google Scholar
• Birk S, Kruuse C, Petersen KA, et al. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004; 24: 1352–1358
   PubMed Web of Science ®Google Scholar
• Birk S, Edvinsson L, Olesen J, et al. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol 2004; 489: 93–100
   PubMed Web of Science ®Google Scholar
• Jackowski A, Crockard A, Burnstock G, et al. The time course of intracranial pathophysiological changes following experimental subarachnoid haemorrhage in the rat. J Cereb Blood Flow Metab 1990; 10: 835–849
   PubMed Web of Science ®Google Scholar
• Meguro T, Clower BR, Carpenter R, et al. Improved rat model for cerebral vasospasm studies. Neurol Res 2001; 23: 761–766
   PubMed Web of Science ®Google Scholar
• Kim KY, Shin HK, Choi JM, et al. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002; 300: 709–715
   PubMed Web of Science ®Google Scholar
• Kim MJ, Park KG, Lee KM, et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 2005; 45: 552–556
   PubMed Web of Science ®Google Scholar
• Watanabe K, Ikeda S, Komatsu J, et al. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol 2003; 92: 21–25
   PubMed Web of Science ®Google Scholar
• Zhao H, Quilley J, Montrose DC, et al. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasocon-striction and CAMP-dependent vasorelaxation following balloon angioplasty. Am J Physiol Heart Circ Physiol 2007; 292: H2973—H2981
   Google Scholar
• Douglas JS, Jr, Holmes DR, Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826–2832
   PubMed Web of Science ®Google Scholar